Daman Partners with Leading Pharma Companies to Help People...

Daman Partners with Leading Pharma Companies to Help People Affected by Rheumatoid Arthritis

Healthcare Tech Outlook | Thursday, December 24, 2020

The relationship arrangement will continue until 15 September 2021, with the possibility of being extended.

FREMONT, CA: Daman, a software product house and digital agency, recently announced that they have signed a partnership agreement with leading pharmaceutical companies Gilead Sciences and Galapagos. The cooperation arrangement will cover 15 global markets. The goal of the Collaboration Agreement is to meet more people living with chronic Rheumatoid Arthritis (RA).

Affecting more than 3 million patients in the EU and 17.6 million worldwide, Rheumatoid Arthritis (RA) puts a high burden on both people, communities, and the healthcare system. Digital healthcare technology, as an adjunct to conventional treatment, offers a tremendous opportunity to offer ongoing, cost-effective, and timely assistance to patients who support behavioral improvements and improve the quality of life of individuals. As exemplified with RheumaBuddy, 13,000+ Rheumatoid Arthritis (RA) patients in Europe have already used RheumaBuddy.

"There is a huge unmet need among RA patients to give more holistic care offerings. The partnership enables us to take important steps in the direction to the benefit of patients and society," says Andreas Dam, CEO, Daman.

The National Rheumatoid Arthritis Society (NRAS) in the United Kingdom has been working alongside Daman for many years and encouraging the RheumaBuddy application for people living with RA in the United Kingdom. Clare Jacklin, CEO, NRAS, said, "RheumaBuddy is a really valuable addition to the patients resource toolkit. The App encourages and promotes better disease self-management and empowers individuals to track and understand their disease progress in a very user-friendly application."

The relationship arrangement will continue until 15 September 2021, with the possibility of being extended. In addition to the new collaboration, Daman began a three-year development project for the RheumaBuddy application in November 2020. Intending to bring the best in class applications to the next level, Daman received EUR 1 million of project funding from the EU and will now continue to reach out to patients and patient organizations interested in joining conferences, being available for interviews evaluate new releases of the application.

In the next six months, new features inspired by co-creation with patients will be added:

• Good consultation, encouraging patients and healthcare practitioners to work together better, maintaining consistency of priorities, reducing confusion, respectively. They will do this with an emphasis on appointments between patients and rheumatologists.

• My Strategy & Target guides and encourages good practices for dealing with and improving RA's quality of life. Knowing the achievable expectations of living with RA is crucial in the right treatment and coping tactics and must balance one's energy levels.

The association arrangement only allows for sponsorship. The actual functionalities and content are still being co-created by patients, healthcare practitioners, and the Daman team.

Weekly Brief